ABIVAX presents first-half 2020 financial results and operations update
(World News Brazil)

ABIVAX PRESENTS FIRST-HALF2020 FINANCIAL RESULTS AND OPERATIONS UPDATE ABX464 Phase 2a ulcerative colitis two-year maintenance study results confirm good safety profile and durable efficacy of 50 mg once-daily oral ABX464 77% (180/232) of patients randomized in ABX464 Phase 2b ulcerative colitis study, recruitment expected to be completed by the end of 2020 ABX464 pivotal Phase 2b/3 trial for Crohn`s disease planned with anticipated start of patient recruitment in Q1 2021 ABX464 Phase 2b/3 Covid-19 study, ABX464 Phase 2a rheumatoid arthritis study and ABX196 Phase 1/2 hepatocellular carcinoma trial all making progress Cash for operations until beginning 2021, with major financing secured...